Artificial cornea transplant is the last frontier for those suffering from serious corneal diseases. Often in these circumstances, traditional cornea transplant is not a valid alternative. The number of artificial cornea transplant operations in the world has grown significantly every year since 2002, when new, more biocompatible and effective artificial cornea models became available. In particular, the Boston Artificial Cornea is increasingly used. In India, where corneal diseases are widespread, a production and development center for Artificial Cornea has been established in Boston. Here a new model of Artificial Cornea called Lucia was conceived.
Artificial cornea transplant can be the ideal solution in cases of extensive corneal neovascularization as a consequence, for example, of herpetic keratitis, or corneal burn from acids or alkalis (e.g. lime or corrosive chemical agents) or stem cell deficiency. The main indication for performing an artificial cornea transplant today is the rejection of the traditional cornea transplant. When a natural cornea transplant is rejected it can be repeated, however the hopes that this transplant will survive are increasingly low. American statistics say that the first corneal transplant has 90% 5-year survival, the second corneal transplant has 50% 5-year survival and the third transplant has less than 20% 5-year survival. For this reason, after the second corneal transplant fails, today there is a tendency to have an artificial cornea transplant rather than proceed with further traditional corneal transplants.

Unfortunately, there are risks associated with the Boston Artificial Cornea. The most important risk is the risk of an infection: for this reason it is essential that the patient carefully follows the doctor’s instructions and undergoes regular checks at a cutting-edge centre. Another associated risk is Glaucoma, which is often already present in these seriously ill eyes and which can worsen after the implantation of the Artificial Cornea, which is why careful monitoring of glaucoma in these patients is essential. In conclusion, today the Boston Keratoprosthesis is a valid solution for a whole series of patients for whom until yesterday we had no alternatives. All patients in whom corneal transplant is not indicated or has already failed today find hope from this innovative intervention. You can find in the testimonials section the stories of patients operated with the artificial cornea in Boston with the hope that this can help give hope to those suffering from serious corneal diseases.


News
You might also be interested in the following news on similar topics: